reports
- Brian Moretta
- Mark Thomas
- Martin Hall
- Riccardo Bindi
Hardman & Co Monthly: April 2023
Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...
INCY INCYTE CORP
IPN IPSEN SA
NOVN NOVARTIS AG
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
REGN REGENERON PHARMACEUTICALS INC.
LLY MERCK & CO. INC.
JNJ ELI LILLY AND COMPANY
J7Z JOHNSON & JOHNSON
HZNP JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
GILD HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
BMY GILEAD SCIENCES INC.
BIIB BRISTOL-MYERS SQUIBB COMPANY
FEV BIOGEN INC.
IBT FIDELITY EUROPEAN VALUES PLC
FCSS INTERNATIONAL BIOTECHNOLOGY TRUST PLC
FSV FIDELITY CHINA SPECIAL SITUATIONS PLC
FJV FIDELITY SPECIAL VALUES PLC
FAS FIDELITY JAPAN TRUST
AVO FIDELITY ASIAN VALUES PLC
CLIG ADVANCED ONCOTHERAPY
MRK CITY OF LONDON INVESTMENT GROUP
NOVO B MERCK KGAA
novob NOVO NORDISK A/S CLASS B
RECI NOVO NORDISK
SAN REAL ESTATE CREDIT INVESTMENTS
UCB SANOFI
HIK UCB S.A.
PIN HIKMA PHARMACEUTICALS PLC
PFIZER PANTHEON INTERNATIONAL
4506 PFIZER
4523 SUMITOMO DAINIPPON PHARMA CO. LTD.
4507 EISAI CO. LTD.
4568 SHIONOGI & CO. LTD.
VTAS DAIICHI SANKYO COMPANY LIMITED
STX VOLTA FINANCE (GBP)
4502 SHIELD THERAPEUTICS
HAT TAKEDA PHARMACEUTICAL CO. LTD.
OCI H&T GROUP
4578 OAKLEY CAPITAL INVESTMENTS
APAX OTSUKA HOLDINGS CO. LTD.
4503 APAX GLOBAL ALPHA
ICGT ASTELLAS PHARMA INC.
UTHR ICG ENTERPRISE TRUST
PFE UNITED THERAPEUTICS CORPORATION
AZN PFIZER INC.
GLAXO ASTRAZENECA PLC
ABBV GLAXOSMITHKLINE PHARMACEUTICALS
VRX CN ASTELLAS PHARMA INC
MRNA ABBVIE INC.
TXG BAUSCH HEALTH COMPANIES INC.
NOVO MODERNA INC.
VTRS 10X GENOMICS INC CLASS A
4568.T NOVO NORDISK A/S-B
ME VIATRIS INC.
OCL DAIICHI SANKYO COMPANY
LUND A LIMITED
23ANDME HLDG CO
OAKLEY CAPITAL
H. LUNDBECK A/S
PFIZER sees a downgrade to Neutral on account of less fundamental star...
The independent financial analyst theScreener just lowered the general evaluation of PFIZER (IN), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date December 28, 2021, the closing price was INR 5,046.95 and its target pric...
- Dave Nicoski
- Ross LaDuke
Vermilion Int'l Compass: Global Equity Strategy
Lower High Forming? Major global indexes are showing waning upside momentum and we believe near-term consolidation is likely. This is supported by the charts and the idea that consolidation makes sense following the massive gains off of the March lows. We also believe that the market is in a “wait-and-see†phase as it relates to states and countries re-opening. A resolution of this consolidation period above resistance (bullish) or below support (bearish) will tell us where the major global...
ERF ENERPLUS CORPORATION
HIK HIKMA PHARMACEUTICALS PLC
YSN SECUNET SECURITY NETWORKS AG
PFIZER PFIZER
TNE TECHNOLOGY ONE
ASTRAZEN ASTRAZENECA PHARMA INDIA LIMITED
6920 LASERTEC CORP.
2345 KUSHIM
600570 HUNDSUN TECHNOLOGIES INC. CLASS A
600436 ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO. LTD. CLASS A
ORNBV ORION OYJ CLASS B
3532 FORMOSA SUMCO TECHNOLOGY
002262 JIANGSU NHWA PHARMACEUTICAL (A)
600764 CHINA MARINE INFORMATION ELECTRONICS (A)
RHHBY ROCHE HOLDING AG ADS
AZN ASTRAZENECA PLC ADS
4385 MERCARI INC.
6669 WIWYNN CORP.
SECT B SECTRA AB B
002901 DOUBLE MEDICAL TECHNOLOGY (A)
- Dave Nicoski
- Ross LaDuke
Vermilion Int'l Compass: Global Equity Strategy
Health Care outperforming globally -- overweight; India breaking out -- add exposure With the primary global ex-U.S. indexes MSCI EAFE, MSCI EM, and MSCI ACWI ex-U.S. continuing their sideways to downward consolidation from a price perspective, the importance of Sector, Group, and stock selection is critical. • Sector and Group Opportunities. Today we put the spotlight on the Health Care Sector, which is assuming a global leadership role as it separates itself from the other international Se...
RHCGF RYMAN HEALTHCARE LTD.
EVT EVOTEC SE
10BC NASPERS LIMITED CLASS N
EL ESSILORLUXOTTICA SA
PSON PEARSON PLC
WKL WOLTERS KLUWER NV
DPH DECHRA PHARMACEUTICALS PLC
MRK MERCK KGAA
SVW SEVEN GROUP HOLDINGS LIMITED
E3G1 EVOLUTION GAMING GROUP AB
SAN SANOFI
FRE FRESENIUS SE & CO. KGAA
ORP ORPEA SA
ABC ABCAM PLC
LUN H. LUNDBECK A/S
DMGT DAILY MAIL & GENERAL TRUST PLC CLASS A
CEVI CELLAVISION AB
SANOFI SANOFI INDIA
PFIZER PFIZER
ABBOTINDIA ABBOTT INDIA
EBO EBOS GROUP
REA REA GROUP LTD
COH COCHLEAR LIMITED
4751 CYBERAGENT INC.
7716 NAKANISHI
6869 SYSMEX CORPORATION
TECN TECAN GROUP AG
STMN STRAUMANN HOLDING AG
T39 SINGAPORE PRESS HOLDINGS LIMITED
ENT ENTAIN PLC
3151 VITAL KSK HOLDINGS
LIFCO B LIFCO AB CLASS B
DIM SARTORIUS STEDIM BIOTECH SA
IPCALAB IPCA LABORATORIES LIMITED
2784 ALFRESA HOLDINGS CORPORATION
2371 KAKAKU.COM INC.
7701 SHIMADZU CORPORATION
SHL SONIC HEALTHCARE LIMITED
9987 SUZUKEN CO. LTD.
DIA DIASORIN S.P.A.
3665 ENIGMO
SPI SPIRE HEALTHCARE GROUP PLC
AZN ASTRAZENECA PLC
TSGI STARS GROUP INC
VIFN VIFOR PHARMA AG
AUP AURORA PROPERTY BUY-WRITE INCOME TRUST
SECT B SECTRA AB B
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.